Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-03

NGNE vs PBYI: stock comparison and AI forecast

Neurogene Inc. (NGNE) and Puma Biotechnology, Inc. (PBYI) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

NGNE Neurogene Inc.

Market Cap
$532M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

PBYI Puma Biotechnology, Inc.

Price
$10.18 +35.2% · 6M
Market Cap
$525M
P/E Ratio
15.7x
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

NGNE · PBYI

Key facts

  • NGNE and PBYI have similar market capitalizations ($532M and $525M).
  • PBYI carries 0.39 times debt per unit of equity, against 0.13 times for NGNE.
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricNGNEPBYI
Market Cap$532M$525M
P/E Ratio–15.66x
P/B Ratio2.45x3.79x
EPS$-5.03$0.65
Book Value/Share$10.85$2.68
Revenue/Share–$4.48
FCF/Share$-4.38$0.80

Profitability & Margins

MetricNGNEPBYI
ROE-51.2%19.3%
ROA-45.5%13.9%
ROIC-54.5%21.3%
Gross Margin–74.8%
Operating Margin–13.2%
Net Margin–11.6%
EBT Margin–13.5%
Tax Rate–13.7%

Financial Health

MetricNGNEPBYI
Current Ratio10.64x2.91x
Quick Ratio–2.64x
D/E Ratio0.13x0.39x
Financial Leverage1.13x1.39x
Interest Coverage6882.5x10.0x
Working Capital$207M$95M

Cash Flow

MetricNGNEPBYI
Operating Cash Flow-$87M$41M
Free Cash Flow-$88M$41M
Capital Spending-$890K$10K
OCF Growth YoY–-7.2%
FCF Growth YoY–-6.9%
FCF/Sales–17.8%
CapEx/Sales–0.0%

Operational Efficiency

MetricNGNEPBYI
Asset Turnover–1.20x
Receivables Turnover–6.8x
Inventory Turnover–4.4x
Fixed Assets Turnover–2245.1x
Days Sales Outstanding–54 days
Days Inventory–84 days
Payables Period–19 days
Cash Conversion Cycle–118 days

Income Statement

MetricNGNEPBYI
Total Revenue–$231M
Operating Income-$121M$30M
Net Income-$111M$27M
R&D Expense$88M$71M
SG&A Expense–$71M
Cost of Goods Sold–$58M

Dividend & Shareholder Information

MetricNGNEPBYI
Shares Outstanding20M52M
Net Income Growth–-44.9%
EPS Growth–-21.7%
FAQ

NGNE vs PBYI: stock comparison and AI forecast

Which is bigger, NGNE or PBYI?

NGNE and PBYI have similar market capitalizations ($532M and $525M).

Which one does Intratio's AI model rank higher, NGNE or PBYI?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.